Generic Suboxone (Buprenorphine/Naloxone): Availability, Cost Savings, and Equivalence

Since 2017, multiple FDA-approved generic buprenorphine/naloxone sublingual tablets have entered the market, dramatically reducing cost and expanding access to medication for opioid use disorder (MOUD).

First Generics Approved (2017)

  • Mylan Pharmaceuticals
  • Alvogen
  • Dr. Reddy's Laboratories
  • Sun Pharmaceutical

Subsequent Approvals

Many additional manufacturers (Teva, Amneal, Actavis, etc.) now market generics. All are AB-rated (bioequivalent to brand Suboxone®).

Formulations

  • Sublingual tablets: 2 mg/0.5 mg, 8 mg/2 mg
  • Sublingual films (generic for Suboxone Film®): Approved later; multiple manufacturers
  • Buccal film (Belbuca® generic) – for pain, not OUD

Clinical Equivalence

  • Same active ingredients, dosage, route, strength, quality.
  • Bioequivalence: 80–125% AUC/Cmax ratios.
  • Inactive ingredients may differ (flavor, color) – rarely clinically relevant.

Access Impact

  • Cost reduction: Generics ~50–80% cheaper than brand
  • Insurance prefer generics (lower copay)
  • Expanded prescriber willingness, patient adherence
  • Critical for addressing opioid crisis treatment gap

Prescribe generics confidently. Ensure pharmacy dispenses prescribed formulation (tablet vs. film).

Prescription Medications - Related Articles